BridgeBio Pharma, Inc.
BBIO
Positions held
Your positionsBBIO isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- BridgeBio Pharma's strong gross margin of 93.8% indicates robust pricing power and efficient production, positioning it well within the competitive biotechnology landscape.
- Revenue increased by 25% compared to the prior quarter, reaching $244 million.
- The gross margin slightly decreased from 94.9% to 93.8%, showing stability in profitability despite fluctuations.
- The company's operating margin remains negative at -44%, reflecting ongoing challenges in managing operational costs.
- BridgeBio reported a net income loss of $152.216 million in Q2 2026, continuing a trend of significant losses.
- The overall score indicates a 'Sell' signal with a score of -5.00, highlighting investor concerns about the company's performance.
Fundamentals
| Market cap | $12.71B | Enterprise value | $15.38B | Trailing P/E | — | Forward P/E | 2,367.67 |
| PEG | — | Price / book | -5.05 | Beta | 0.97 | Dividend yield | 0.00% |
| Revenue growth | 120.4% | Earnings growth | — | Gross margin | 94.4% | Operating margin | -43.9% |
| Profit margin | -97.0% | ROE | — | ROA | -26.0% | Debt / equity | — |
| Current ratio | 1.23 | Free cash flow | -$320.26M | Analyst recommendation | strong_buy | Mean target | $109.05 |
| 52w high | $93.42 | 52w low | $52.75 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $244M | $195M | $154M | $121M | $111M | — |
| Op margin | -43.9% | -54.5% | -83.3% | -113.0% | -120.7% | — |
| Net income | -$152M | -$164M | -$193M | -$183M | -$182M | — |
| Gross margin | 93.8% | 94.9% | 94.7% | 94.6% | 96.7% | — |
| Gross profit | $229M | $185M | $146M | $114M | $107M | — |
| Operating income | -$107M | -$106M | -$128M | -$136M | -$133M | — |
- Revenue +25% vs prior quarter ($244M vs $195M).
- Gross margin 93.8% (was 94.9% prior quarter).
- Operating margin expanded to -44%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $502M | $222M | $9.3M | $77.6M | — |
| Op margin | -100.0% | -260.2% | -6443.6% | -603.3% | — |
| Net income | -$725M | -$536M | -$643M | -$481M | — |
| Gross margin | 95.8% | 98.3% | 73.7% | 95.6% | — |
| Gross profit | $481M | $218M | $6.9M | $74.2M | — |
| Operating income | -$502M | -$577M | -$599M | -$468M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
2026-10-06 · BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
2026-10-06 · Sector Update: Healthcare Stocks Rise Premarket Tuesday
2026-10-06 · BridgeBio Pharma's New Drug Application for Genetic Short Stature Condition Accepted by US FDA
2026-10-06 · BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
2026-10-05 · BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
2026-09-30 · Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
2026-09-27 · The Bull Case For BridgeBio Pharma (BBIO) Could Change Following New ATTR Data Versus Tafamidis
Price (daily)
Full chart · RSI · MACD · patterns